Teva Adds To Biosimilars Capabilities Through Partnership With Lonza
This article was originally published in The Pink Sheet Daily
Executive Summary
Israeli generic giant, Swiss CMO announce joint venture to co-develop, manufacture and market biosimilars.
You may also be interested in...
Three Largest U.S. Generic Firms See Diversification As Best Path Through Reverse Patent Cliff
Expanded technological capabilities, narrowed focus on alternative dosage forms and harder-to-replicate products, and growing international reach are among the strategies being employed by Teva, Mylan and Watson in the face of 2013’s anticipated reverse patent cliff.
Playing Catch-Up: Mylan And Biocon To Team Up On Generic Biologics
U.S. generics giant and Indian biotech hope their collaboration will position them against Teva/Lonza, Sandoz, and other potential competitors.
Playing Catch-Up: Mylan And Biocon To Team Up On Generic Biologics
U.S. generics giant and Indian biotech hope their collaboration will position them against Teva/Lonza, Sandoz, and other potential competitors.